Research programme: metabolic disorders therapeutics - Synageva BioPharma/BBB Therapeutics

Drug Profile

Research programme: metabolic disorders therapeutics - Synageva BioPharma/BBB Therapeutics

Latest Information Update: 07 Oct 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synageva BioPharma
  • Class Proteins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Metabolic disorders

Most Recent Events

  • 07 Oct 2014 No development reported for Metabolic disorders in USA (Parenteral)
  • 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics
  • 07 Jan 2011 Early research in Metabolic disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top